AngioDynamics (ANGO) Q4 2026: MedTech Share Hits 48%, Underpinning 18% Segment Growth
AngioDynamics accelerated its MedTech transformation in Q4, with the segment now nearly half of total revenue and delivering robust double-digit growth. Strategic execution in cardiovascular and interventional oncology platforms drove above-market share gains, even as tariffs and investment spending weighed on bottom-line results. The company’s 2027 outlook signals continued MedTech outperformance, balanced by disciplined R&D and a debt-free balance sheet to support long-term growth.
Summary
- MedTech Mix Shift: MedTech now comprises nearly half of total sales, reflecting a deliberate pivot to higher-growth markets.
- Platform Execution: Arion and NanoKnife platforms continue to outperform, driving share gains and clinical adoption.
- Investment-Led Growth: Ongoing R&D and clinical spend position AngioDynamics for sustained outperformance in large, expanding markets.
Business Overview
AngioDynamics is a medical technology company specializing in minimally invasive devices for vascular, interventional oncology, and peripheral disease treatments. The business generates revenue through two primary segments: MedTech, focused on high-growth, innovative platforms such as Arion (atherectomy), AlphaVac/AngioVac (mechanical thrombectomy), and NanoKnife (irreversible electroporation for tumor ablation); and Med Device, a stable, cash-generative portfolio of foundational medical devices supporting ongoing investment in MedTech innovation.
Performance Analysis
AngioDynamics delivered another quarter of robust top-line expansion, with total revenue up 8% and MedTech revenue surging 16.7% year-over-year. The MedTech segment’s share of total sales rose to 48%, up from 45% a year ago, highlighting a structural business mix shift toward higher-margin, faster-growing categories. Arion, the atherectomy platform, delivered its 20th consecutive quarter of double-digit growth, benefiting from both hospital and outpatient (OBL) channel expansion and international adoption post-CE mark. NanoKnife posted standout results, with revenue up 64.5%—record procedure volumes in prostate care and new reimbursement wins underpinning momentum.
Mechanical thrombectomy performance was mixed: AlphaVac grew 38% in the quarter, offset by a 16% decline in AngioVac, reflecting market lumpiness and competitive intensity. Gross margin expanded 130 basis points to 54% as MedTech mix improved, though tariffs and higher operating expenses pressured profitability. Adjusted EBITDA was stable year-over-year, while cash generation remained positive despite absorbing $4.8 million in annual tariff costs and proactive inventory actions.
- MedTech Outperformance: MedTech segment grew 18% for the year, now 47% of revenue, up from 22% in 2020.
- Arion Platform Consistency: Delivered double-digit growth for 20 consecutive quarters, reinforcing product leadership.
- NanoKnife Acceleration: Record procedure volumes and strong disposable sales signal accelerating adoption in prostate care.
Med Device revenue was stable, growing 1.1% in Q4 and 2.5% for the year, providing a reliable cash foundation for ongoing MedTech investment. Despite higher R&D and SG&A, AngioDynamics maintained a debt-free balance sheet and generated positive operating cash flow, supporting future growth initiatives.
Executive Commentary
"Our MedTech segment was 47% of our total revenue this year, up from roughly 22% at the end of fiscal 2020. Over the past six years, that business has grown at a compound annual rate of approximately 24%, and we have done all of this while driving sustained profitability."
Jim Clemmer, President and Chief Executive Officer
"Adjusted EBITDA on the full fiscal year 2026 was $13.2 million, compared to $7.6 million in fiscal year 2025. This year-over-year improvement is largely attributable to our MedTech revenue growth and the success of our gross margin and operating efficiency initiatives, and we delivered it while absorbing tariff costs that were not in our business a year ago."
Steve Trowbridge, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. MedTech Mix Shift and Market Share Gains
AngioDynamics has deliberately reweighted its portfolio toward MedTech, with segment growth far outpacing legacy Med Device revenue. MedTech now accounts for nearly half of total sales, up from just over a fifth in 2020, reflecting a multi-year transformation targeting large, fast-growing cardiovascular and oncology markets. This mix shift is central to the company’s long-term value creation strategy.
2. Platform Innovation and Clinical Data Investment
Platform leadership in Arion and NanoKnife is supported by ongoing clinical data generation and regulatory wins. The company is investing approximately 10% of sales in R&D, fueling pivotal trials and expanding indications—such as the Alpha Return blood management system and NanoKnife’s new BPH feasibility study. Recent Medicare and private payer reimbursement progress further supports adoption and market expansion.
3. Commercial Execution and Competitive Response
AngioDynamics responded to competitive intensity in mechanical thrombectomy with commercial team restructuring and targeted hiring. The company is focused on accelerating account penetration and clinical training, especially for AlphaVac, to capitalize on the ongoing shift from lytic-based to mechanical interventions. Management expects these changes to drive improved growth in FY27.
4. Operating Discipline and Cash Generation
Despite elevated tariff and operating expense headwinds, AngioDynamics maintained positive cash flow and a debt-free balance sheet. The Med Device segment continues to provide stable cash generation, funding MedTech investments without leveraging the balance sheet, and enabling flexibility to absorb external shocks while supporting growth initiatives.
5. Leadership Transition and Continuity
CEO Jim Clemmer will retire in FY27, with a search underway for a successor. The transition is being managed to ensure strategic and operational continuity, with Clemmer and CFO Steve Trowbridge committed to a seamless handoff and ongoing execution of the current growth strategy.
Key Considerations
This quarter underscores AngioDynamics’ execution of a multi-year pivot from slow-growth, commoditized devices to differentiated, high-growth MedTech platforms. The company’s ability to fund innovation while expanding profitability, even amid tariff and competitive pressures, signals a resilient business model. Investors should monitor:
- MedTech Adoption Trajectory: Continued share gains in Arion and NanoKnife, particularly as reimbursement hurdles are cleared and new clinical data is published.
- Mechanical Thrombectomy Growth: Execution on commercial changes and competitive response will determine the pace of AlphaVac and AngioVac recovery.
- Clinical and Regulatory Catalysts: Milestones in pivotal trials, BPH indication expansion, and national coverage decisions could unlock further market opportunities.
- Operating Leverage Realization: Balance between investment in growth and margin expansion as MedTech scales and R&D normalizes near the 10% target.
Risks
Competitive intensity remains high in core markets, especially in mechanical thrombectomy, where larger players are shifting go-to-market strategies. Tariff unpredictability and reimbursement delays could pressure margins and adoption rates. Execution risk is elevated during the CEO transition, with continuity of strategy and talent retention critical for maintaining momentum. Investors should also watch for lumpiness in capital sales and seasonality in procedure volumes, particularly in NanoKnife.
Forward Outlook
For FY27, AngioDynamics guided to:
- Net sales of $336 to $341 million, representing 5% to 6.5% growth
- MedTech sales growth of 12% to 15%, Med Device roughly flat
- Gross margin of 54% to 55%
- Adjusted EBITDA of $13 to $16 million
- Adjusted loss per share of $0.29 to $0.24
Management expects tariff impacts similar to FY26 and highlighted continued investment in clinical data and commercial expansion as key drivers. Q1 is expected to be seasonally lower in revenue and cash generation, with growth building through the year as MedTech adoption accelerates.
Takeaways
- MedTech Transformation: The company’s deliberate shift to MedTech is driving above-market growth, improved margins, and a stronger competitive position, though profitability is still being reinvested for future scale.
- Execution Levers: Commercial restructuring and clinical investment are aimed at unlocking further growth in mechanical thrombectomy and expanding NanoKnife’s addressable market.
- Watch for Margin Inflection: As MedTech scales and R&D spend normalizes, operating leverage and free cash flow could improve, providing upside to the current investment thesis.
Conclusion
AngioDynamics’ Q4 and FY26 results validate its MedTech-led strategy, with strong execution in key platforms and disciplined investment supporting sustained outperformance. While external headwinds and operational investments are weighing on near-term profitability, the company’s business model and balance sheet position it well for continued growth and value creation in FY27 and beyond.
Industry Read-Through
AngioDynamics’ results reinforce the sector-wide migration toward high-growth, procedure-driven MedTech platforms and highlight the importance of clinical data and reimbursement in driving adoption. The company’s ability to expand share in competitive cardiovascular and oncology markets signals opportunity for differentiated technologies, while tariff and margin pressures remain a broader industry challenge. The focus on balancing innovation investment with cash generation is increasingly relevant for other device makers seeking to navigate similar market and regulatory dynamics.